Long-term update of the 24954 EORTC phase III trial on larynx preservation
B. Henriques de Figueiredo(Cliniques Universitaires Saint-Luc), Vincent Grégoire(Centre Léon Bérard), Frédéric Rolland(Institut de Cancérologie de l'Ouest), Lisa Licitra(University of Milan), Luigi Barzan(Azienda Ospedaliera Santa Maria Degli Angeli), Catherine Fortpied(European Organisation for Research and Treatment of Cancer), L. Giurgea(European Organisation for Research and Treatment of Cancer), C. René Leemans(Amsterdam UMC Location VUmc), Lionnel Geoffrois(Institut de Cancérologie de Lorraine), D. De Raucourt(Centre Hospitalier Universitaire de Nantes), P. Hupperets(Maastricht University Medical Centre), Jean Louis Lefèbvre(Centre Oscar Lambret), Margot Tesselaar(Leiden University Medical Center), Jan B. Vermorken(University of Antwerp), Jessica Menis(University of Verona)
Cited by 45
Related Papers
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
The molecular landscape of head and neck cancer
|Nature reviews. Cancer|2018|1.4k